共 50 条
The Role of Endocannabinoid System in Neuroprotection: Molecular Targets and Therapeutic Opportunities
被引:1
|作者:
Thapa, Sonia
[1
,2
]
Singh, Shashank K.
[1
,2
]
机构:
[1] CSIR Indian Inst Integrat Med, Canc Pharmacol Div, Canal Rd, Jammu 180001, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad, India
来源:
关键词:
cannabinoids;
neurotransmitters;
pain;
cannabinoid receptors;
neurological disorders;
CB1;
CANNABINOID-RECEPTOR;
NEUROPATHIC PAIN;
ALZHEIMERS-DISEASE;
NEURODEGENERATIVE DISEASES;
ABNORMAL-CANNABIDIOL;
SELECTIVE ANTAGONIST;
PARTIAL AGONIST;
FULL AGONIST;
GLUTAMATE;
ACTIVATION;
D O I:
10.1089/imr.2022.0091
中图分类号:
R [医药、卫生];
学科分类号:
10 ;
摘要:
Objective: To describe the endocannabinoid system, cannabinoid receptors, its agonism/antagonism in neurodegenerative disorders.Introduction: The endocannabinoid system (ECS) represents a highly complex biological system that synthesize and degrade the endocannabinoids. Cannabinoids are endogenous lipid-based neurotransmitters, work in retrograde manner, that bind to a class of G protein-coupled receptors (GPCRs) known as CBRs, of two types: CB1R and CB2R.Results: The literature review suggests that the endocannabinoids regulate cognitive processes, fertility, pregnancy, immune homeostasis, appetite, pain, pain sensation, memory, and behavior. Both CB1 and CB2 couple mainly to inhibitor G proteins and having same pharmacological influences as other GPCRs. Thus, selective/partial agonism, functional selectivity/activity, and inverse agonism all play vital activities in determining the cellular response to specific CBR and ligand interactions.Conclusion: Improved therapeutic modalities for neurological disorders and the development of novel molecular targets for therapeutic intervention of neuronal diseases require a full understanding of the cross-talk between CB1, cannabinoids, and pathophysiology of neurodegenerative disease.
引用
收藏
页码:72 / 86
页数:15
相关论文